Inhibition of the growth of hepatocellular carcinoma cells through fibroblast growth factor 18 suppressed by miR-139

Yang,Li; Yin,Dian; Wang ,Yilang; Cao,Lili

doi:10.3892/or.2017.5869

Inhibition of the growth of hepatocellular carcinoma cells through fibroblast growth factor 18 suppressed by miR-139

Authors:
- Li Yang
- Dian Yin
- Yilang Wang
- Lili Cao
View Affiliations

Affiliations: Department of Oncology, The First People's Hospital of Nantong, Nantong, Jiangsu 226001, P.R. China
Published online on: August 2, 2017 https://doi.org/10.3892/or.2017.5869
Pages: 2565-2571

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a highly malignant tumor and one of the most common causes for human cancer-related deaths. Fibroblast growth factor 18 (FGF18) is overexpressed in many types of cancer, and is associated with cell proliferation, invasion and angiogenesis. miR-139 has recently been reported as a tumor suppressor in various types of cancer and it can regulate many tumor-related genes, however its association with FGF18 expression in HCC has not been reported and thus remains unknown. In the present study, to explore the potential regulation mechanism of miR-139 with FGF18 in HCC, HCC tissues and cell lines were used. The results revealed that FGF18 was highly expressed in HCC tissues and cells, however miR-139 was lowly expressed. FGF18 was demonstrated to be a direct target of miR-139. Furthermore, the suppressive effect of miR-139 on FGF18 and in turn on proliferation, apoptosis, invasion, migration and tumor-induced angiogenesis of HCC cells was investigated. FGF18 was suggested as a prognostic biomarker and therapeutic target in HCC patients and miR-139 may be a promising strategy used in HCC treatment via the suppression of FGF18.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Wang C, Zhang F, Fan H, Peng L, Zhang R, Liu S and Guo Z: Sequence polymorphisms of mitochondrial D-loop and hepatocellular carcinoma outcome. Biochem Biophys Res Commun. 406:493–496. 2011. View Article : Google Scholar : PubMed/NCBI
4	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
5	Shindoh J, Hasegawa K, Inoue Y, Ishizawa T, Nagata R, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M and Kokudo N: Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB Oxf. 15:31–39. 2013. View Article : Google Scholar
6	Hu MC, Qiu WR, Wang YP, Hill D, Ring BD, Scully S, Bolon B, DeRose M, Luethy R, Simonet WS, et al: FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation. Mol Cell Biol. 18:6063–6074. 1998. View Article : Google Scholar : PubMed/NCBI
7	Cinque L, Forrester A, Bartolomeo R, Svelto M, Venditti R, Montefusco S, Polishchuk E, Nusco E, Rossi A, Medina DL, et al: FGF signalling regulates bone growth through autophagy. Nature. 528:272–275. 2015. View Article : Google Scholar : PubMed/NCBI
8	Liu Z, Lavine KJ, Hung IH and Ornitz DM: FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev Biol. 302:80–91. 2007. View Article : Google Scholar : PubMed/NCBI
9	Hung IH, Schoenwolf GC, Lewandoski M and Ornitz DM: A combined series of Fgf9 and Fgf18 mutant alleles identifies unique and redundant roles in skeletal development. Dev Biol. 411:72–84. 2016. View Article : Google Scholar : PubMed/NCBI
10	Dahlberg LE, Aydemir A, Muurahainen N, Gühring H, Edebo Fredberg H, Krarup-Jensen N, Ladel CH and Jurvelin JS: A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis. Clin Exp Rheumatol. 34:445–450. 2016.PubMed/NCBI
11	Itoh N, Nakayama Y and Konishi M: Roles of FGFs as paracrine or endocrine signals in liver development, health, and disease. Front Cell Dev Biol. 4:302016. View Article : Google Scholar : PubMed/NCBI
12	Davidson D, Blanc A, Filion D, Wang H, Plut P, Pfeffer G, Buschmann MD and Henderson JE: Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J Biol Chem. 280:20509–20515. 2005. View Article : Google Scholar : PubMed/NCBI
13	Koneczny I, Schulenburg A, Hudec X, Knöfler M, Holzmann K, Piazza G, Reynolds R, Valent P and Marian B: Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. Mol Carcinog. 54:789–799. 2015. View Article : Google Scholar : PubMed/NCBI
14	El-Gendi S, Abdelzaher E, Mostafa MF and Sheasha GA: FGF18 as a potential biomarker in serous and mucinous ovarian tumors. Tumour Biol. 37:3173–3183. 2016. View Article : Google Scholar : PubMed/NCBI
15	Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G and Birrer MJ: FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest. 123:4435–4448. 2013. View Article : Google Scholar : PubMed/NCBI
16	Sonvilla G, Allerstorfer S, Stättner S, Karner J, Klimpfinger M, Fischer H, Grasl-Kraupp B, Holzmann K, Berger W, Wrba F, et al: FGF18 in colorectal tumour cells: Autocrine and paracrine effects. Carcinogenesis. 29:15–24. 2008. View Article : Google Scholar : PubMed/NCBI
17	Flannery CA, Fleming AG, Choe GH, Naqvi H, Zhang M, Sharma A and Taylor HS: Endometrial cancer-associated FGF18 expression is reduced by bazedoxifene in human endometrial stromal cells in vitro and in murine endometrium. Endocrinology. 157:3699–3708. 2016. View Article : Google Scholar : PubMed/NCBI
18	Forner A: Hepatocellular carcinoma surveillance with miRNAs. Lancet Oncol. 16:743–745. 2015. View Article : Google Scholar : PubMed/NCBI
19	Hayes CN and Chayama K: MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma. Int J Mol Sci. 17:2802016. View Article : Google Scholar : PubMed/NCBI
20	Shen S, Lin Y, Yuan X, Shen L, Chen J, Chen L, Qin L and Shen B: Biomarker microRNAs for diagnosis, prognosis and treatment of hepatocellular carcinoma: A functional survey and comparison. Sci Rep. 6:383112016. View Article : Google Scholar : PubMed/NCBI
21	Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Soifer HS, Rossi JJ and Saetrom P: MicroRNAs in disease and potential therapeutic applications. Mol Ther. 15:2070–2079. 2007. View Article : Google Scholar : PubMed/NCBI
24	Baker M: RNA interference: MicroRNAs as biomarkers. Nature. 464:12272010. View Article : Google Scholar : PubMed/NCBI
25	Cui L, Zhang X, Ye G, Zheng T, Song H, Deng H, Xiao B, Xia T, Yu X, Le Y, et al: Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 119:1618–1626. 2013. View Article : Google Scholar : PubMed/NCBI
26	Li HC, Chen YF, Feng W, Cai H, Mei Y, Jiang YM, Chen T, Xu K and Feng DX: Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway. Gene. 603:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
27	Krowiorz K, Ruschmann J, Lai C, Ngom M, Maetzig T, Martins V, Scheffold A, Schneider E, Pochert N, Miller C, et al: MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia. Blood Cancer J. 6:e5082016. View Article : Google Scholar : PubMed/NCBI
28	Yonemori M, Seki N, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M and Enokida H: Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Sci. 107:1233–1242. 2016. View Article : Google Scholar : PubMed/NCBI
29	Liu H, Yin Y, Hu Y, Feng Y, Bian Z, Yao S, Li M, You Q and Huang Z: miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. Pathol Res Pract. 212:643–649. 2016. View Article : Google Scholar : PubMed/NCBI
30	Huang P, Xi J and Liu S: MiR-139-3p induces cell apoptosis and inhibits metastasis of cervical cancer by targeting NOB1. Biomed Pharmacother. 83:850–856. 2016. View Article : Google Scholar : PubMed/NCBI
31	Sun C, Sang M, Li S, Sun X, Yang C, Xi Y, Wang L, Zhang F, Bi Y, Fu Y, et al: Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget. 6:39756–39792. 2015. View Article : Google Scholar : PubMed/NCBI
32	Li Q, Liang X, Wang Y, Meng X, Xu Y, Cai S, Wang Z, Liu J and Cai G: miR-139-5p inhibits the epithelial-mesenchymal transition and enhances the chemotherapeutic sensitivity of colorectal cancer cells by downregulating BCL2. Sci Rep. 6:271572016. View Article : Google Scholar : PubMed/NCBI
33	Chen H, Xu H, Meng YG, Zhang Y, Chen JY and Wei XN: miR-139-5p regulates proliferation, apoptosis, and cell cycle of uterine leiomyoma cells by targeting TPD52. Onco Targets Ther. 9:6151–6160. 2016. View Article : Google Scholar : PubMed/NCBI
34	Dai S, Wang X, Li X and Cao Y: MicroRNA-139-5p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme. Biochem Biophys Res Commun. 467:204–210. 2015. View Article : Google Scholar : PubMed/NCBI